Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 4/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578782 | 1.00 | USP2 (0.60) | USP2KDM4ECASRHRH1CCR3 | |
| SCHEMBL8228558 | 1.00 | USP2 (0.60) | USP2KDM4ECASRHRH1CCR3 | |
| SCHEMBL1664075 | 0.91 | USP2 (0.69) | USP2KDM4EHRH1CCR3KCNH2 | |
| SCHEMBL10184117 | 0.84 | ACACB (0.46) | USP2ACACBUSP30 | |
| SCHEMBL21638239 | 0.84 | LIPG (0.53) | USP2KDM4ECASRHRH1CCR3 | |
| SCHEMBL21669125 | 0.84 | LIPG (0.53) | USP2KDM4ECASRHRH1CCR3 | |
| SCHEMBL21638237 | 0.84 | LIPG (0.53) | USP2KDM4ECASRHRH1CCR3 | |
| SCHEMBL23839398 | 0.82 | HTT (0.50) | ACACB | |
| SCHEMBL23839396 | 0.82 | HTT (0.50) | ACACB | |
| SCHEMBL13486520 | 0.80 | NOTUM (0.50) | ACACBUSP30NOTUMFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117136187-A | Novel anti-hepatitis B compound | 上海齐鲁制药研究中心有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | USP2 32/4885KDM4E 713/4885CASR 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.